|Calculated MW||68746 Da|
|Homology||Mouse - 14/15 amino acid residues identical.|
|Other Names||Sodium-dependent dopamine transporter, DA transporter, DAT, Solute carrier family 6 member 3, Slc6a3|
|Related products for control experiments||Control peptide antigen (supplied with the antibody free of charge).|
|Target/Specificity||Peptideֲ (C)DAHASNSSDGLGLND, corresponding to amino acids residues 191-205 of rat Dopamine Transporter (Accession P23977). Extracellular, 2nd loop.Not recommended for use with human samples.|
|Peptide Confirmation||Confirmed by mass-spectrography and amino acid analysis.|
|Format||Affinity purified antibody, lyophilized powder|
|Reconstitution||50 µl or 0.2 ml deionized water, depending on the sample size.|
|Antibody Concentration After Reconstitution||0.8 mg/ml.|
|Buffer After Reconstitution||Phosphate buffered saline (PBS), pH 7.4, 1% BSA, 0.025% NaN3.|
|Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Storage After Reconstitution||The reconstituted solution can be stored at 4ºC for up to 2 weeks. For longer periods, small aliquots should be stored at -20ºC or below. Avoid multiple freezing and thawing. The further dilutions should be made using a carrier protein such as BSA (1%). Centrifuge all antibody preparations before use (10000 × g 5 min).|
|Control Antigen Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Control Antigen Reconstitution||100 µl water.|
|Control Antigen Storage After Reconstitution||-20ºC.|
|Preadsorption Control||1 µg peptide per 1 µg antibody.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The Na+/Cl- transporter family, SLC6, includes DAT a monoamine transporter, important for regulating extracellular levels of dopamine. It does so by uptaking dopamine from the synaptic cleft via the co-transport of Na+ and Cl- down their electrochemical gradient1. The removal of dopamine by DAT remains the most important means to control the extracellular lifetime of the neurotransmitter, and notably the ending of dopaminergic neurotransmission2. Transporters for serotonin, norepinephrine, GABA and glycine also belong to this family3. These receptors have 12 transmembrane spanning domains and intracellular N- and C-terminal domains. DAT is also subjected to post translational modifications such phosphorylation, important for its regulation1. Also, it possesses a large extracellular domain which undergoes N-glycosylation, important for the proper targeting of the transporter to the plasma membrane1. DAT is expressed in dopaminergic cell bodies and terminals and can therefore serve as a marker for these neurons4. DAT is also expressed in the retina, gastrointestinal tract, lung, kidney, pancreas and lymphocytes2. DAT plays an important role in movement as well as reward, learning and memory5. Its malfunction which leads to dopaminergic dysregulation has been associated with ADHD, schizophrenia, as well as Parkinson’s disease2. DAT is the main target for cocaine and amphetamine and methamphetamine psychostimulants, which mainly increase locomotor activities2. Abgent is pleased to offer a highly specific antibody directed against an extracellular epitope of rat dopamine transporter. Anti-Dopamine Transporter (DAT) (extracellular) antibody (#AG1205) can be used for western blot and immunocytochemistry applications. It has been designed to recognize DAT from mouse and rat samples.
References 1. Robertson, S.D. et al. (2009) Mol. Neurobiol. 39, 73. 2. Gainetdinov, R.R. (2008) Nauyn-Schiedeberg’s Arch. Pharmacol. 377, 301. 3. Torres, G.E. and Amara, S.G. (2007) Curr. Opin. Neurobiol. 17, 304. 4. Ciliax, B.J. et al. (1995) J. Neurosci. 15, 1714. 5. Uhl, G.R. (2003) Mov. Disord. 18, suppl 7, S71.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.